CD8A and neoplasm: We[146] and a recent series of reviews[151,154,155] have detailed the reported evidence showing that GSK3β attenuates the ability of anti-tumor immunocellular arsenals such as NK cells, CD8+ T-cell-derived pluripotent memory stem T-cells with cytotoxic capacity, and tumor-type specific genetically engineered chimeric antigen receptor (CAR)-T cells.